LYPHE Group imports flower-based cannabis products to UK

Supplies of flower-based medical cannabis products available in the UK are continuing to grow, as the LYPHE Group imports Northern Green Canada into the market.

LYPHE Group, one of the main medical cannabis providers, with more than 60 percent of the British patient market, has entered into a supply partnership with Canadian manufacturer, Northern Green.

The partnership will see a range of indoor grown flowers enter the UK market under the brand name of NOIDECS.

The flowers are now available in the private market and through NOIDECS’ inclusion on the formulary of Europe’s largest patient real world data registry, Drug Science’s Project Twenty21.

LYPHE Group announced its partnership with Project Twenty21 in December to bring a range of EU-GMP and equivalent GMP medicines to the UK.

Twenty21 is seen as one of the most respected research programmes into cannabinoid medicine in Europe and is collecting substantial evidence based on the efficacy and safety profile of medical cannabis across a range of conditions, which, when successful, it hopes will open the door for NHS access.

The growing range of NOIDECS products is welcome news for the UK market, which has historically struggled with consistent supply of flower-based medical cannabis products.

It also adds to the long line of products stocked by LYPHE Group pharmacy, Dispensary Green, which stocks more than 80 percent of all available brands in the market.

The move comes just weeks after UK distributor, Grow Pharma reached an agreement with global cannabis producer Tilray.

Under the agreement, NOIDECS is also expanding the range into other international territories.

Speaking of the new partnership, Dean Friday, CEO of LYPHE Group said in a press release: “We are pleased to welcome the talented team at Northern Green Canada into the UK market and consider them an important strategic supply partner as we begin the march across Europe and further afield with NOIDECS.”

Northern Green Canada CEO, Lisa McCormack added: “We are delighted to support LYPHE Group as they build their NOIDECS range into a mainstay of the UK and European markets.

“Northern Green Canada’s approach is always focused on the production of quality medicine, and our EU GMP-certified products are a testament to this achievement.”